--- title: 'Regulatory Daily Summary: What Happened on October 7, 2026' headline: EU adds selected high-risk devices to joint assessment process description: The EU began applying joint clinical assessment rules to some medicines in January 2025. Orphan medicines are scheduled to follow in 2028. url: https://thebench.bio/news/regulatory/2026-10-07 topic: regulatory date: '2026-10-07' covers: - '2026-10-07' date_published: '2026-10-07T12:02:28Z' date_modified: '2026-10-07T12:02:28Z' sources: 1 publisher: The Bench (thebench.bio) --- # Regulatory Daily Summary: What Happened on October 7, 2026 **EU adds selected high-risk devices to joint assessment process** The EU began applying joint clinical assessment rules to some medicines in January 2025. Orphan medicines are scheduled to follow in 2028. ## Today in brief The EU began applying joint clinical assessment rules to new oncology medicines and advanced therapy medicinal products in January 2025. [1] In June 2026, its member-state coordination group began introducing assessments for selected high-risk medical devices. [1] ## Also worth knowing - The rules are scheduled to cover orphan medicines from January 2028 and all other medicines by 2030. The assessment process also covers Norway, the United Kingdom, Switzerland and Ukraine. [1] ## The day in numbers - **2030**: Deadline for all other medicines to comply with the EU joint clinical assessment rules. [1] - **January 2028**: Scheduled start of assessments for orphan medicines. [1] ## Sources 1. [Countdown to JCA: What APAC and US Drug Developers Need to Know and do Today](), Pharmaceutical Executive, 2026-10-07 --- The Bench wrote this from the reporting cited above, with a language model drafting and editing. [1]: